editor daily mirror
Dailymirror.news,India, March 13, 2025: Glenmark Pharmaceuticals Ltd., a global research-driven pharmaceutical company, has introduced Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been launched under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin + Linagliptin) and Glempa-M (Empagliflozin + Metformin).
These medications aim to enhance glycemic control in adults with Type 2 Diabetes Mellitus (T2DM) and improve cardiovascular outcomes in patients with existing CV risks.
ఇది కూడా చదవండి…సొంత వాటా నుంచి ప్రూడెంట్ షేర్లను బహుమతిగా అందజేస్తున్న ప్రమోటర్ సంజయ్ షా
ఇది కూడా చదవండి…“సామ్సంగ్ గెలాక్సీ బుక్5 సిరీస్ పిసిల విడుదల
ఇది కూడా చదవండి…“వీవింగ్ ది ఫ్యూచర్ – హ్యాండ్లూమ్ కొలోక్వియం సదస్సు విజయవంతంగా ముగిసింది”
Empagliflozin is a globally established treatment for heart failure (HF), Type 2 Diabetes (T2DM), and diabetes-related cardiovascular disease (CVD). Clinical studies, including the EMPA-REG trial, have demonstrated a 14% reduction in major cardiovascular events, reinforcing Empagliflozin’s role in addressing high-risk T2DM patients.
Additional studies highlight the effectiveness of Empagliflozin in combination with other diabetes medications:
- Empagliflozin + Metformin (Glempa-M): A 24-week study found that this combination significantly reduced HbA1c levels (by 1.9% to 2.1%), lowered fasting blood sugar (by 43.2 to 50.4 mg/dL), and contributed to weight loss (3 to 3.8 kg).
- Empagliflozin + Linagliptin (Glempa-L): Another 24-week study showed HbA1c reductions of 1.24%, weight loss of 2 to 2.7 kg, and fasting blood sugar reduction of 28.21 to 29.55 mg/dL, demonstrating superior efficacy compared to individual treatments.
Speaking on the launch, Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals Ltd., stated:”Glenmark has a strong legacy of introducing innovative and accessible treatments for cardiometabolic care in India. The launch of the Glempa range reinforces our commitment to providing comprehensive and affordable solutions that empower healthcare professionals and patients in managing diabetes with cardiovascular risks more effectively.”
Read this also…Synchrony India Recognized Among Top 50 Best Workplaces for Innovation in 2025
Read this also…Swadesh Honors Women Champions of Craft & Creative Traditions on Women’s Day
The Glempa range caters to diverse patient needs with three tailored options:
Glempa (Empagliflozin 10mg/25mg) – A standalone SGLT2 inhibitor for glycemic control and cardiovascular risk reduction.
Glempa-L (Empagliflozin + Linagliptin) – A dual-action therapy combining an SGLT2 inhibitor and a DPP4 inhibitor for improved T2DM management.
Glempa-M (Empagliflozin + Metformin) – A combination therapy providing enhanced glucose regulation.
With the rising burden of diabetes and cardiovascular diseases, Glenmark’s Glempa range is poised to provide affordable, high-quality treatment options, improving health outcomes for millions of patients across India.
